Alvotech Secures $75M Term Loan to Bolster Liquidity Amid Ongoing Regulatory Challenges

What happened

Alvotech amended its credit agreement with GoldenTree and other lenders to secure a $75 million term loan facility, adding liquidity to its balance sheet. The move follows a ~65% share decline after the FDA issued a complete response letter for AVT05 in November 2025, which highlighted persistent manufacturing deficiencies at its single Reykjavik facility and forced a sharp guidance cut. While the additional $75 million increases total secured debt to roughly $1.175 billion and deepens negative equity, it provides near-term cash to fund remediation and operations without an immediate dilutive equity raise. The loan indicates lender support but also comes with tighter covenants that could trigger strain if 2026 EBITDA fails to meet projections. Ultimately, this is a bridging measure that buys time, but does not resolve the core need for AVT05 approval and sustainable positive free cash flow.

Implication

Success now hinges entirely on whether Alvotech can achieve AVT05 U.S. approval and ramp European launches to generate cash flow that services the expanded debt. If remediation succeeds and revenue materializes, this loan will have been a smart bridge; if not, the additional $75 million worsens an already strained balance sheet and increases dilution risk in a restructuring scenario.

Thesis delta

The loan extends Alvotech's cash runway and pushes back the threat of a near-term liquidity crisis, but it does not improve the underlying regulatory or competitive outlook. The core thesis remains 'wait' — we need evidence of AVT05 remediation success and sustained product-driven EBITDA before considering entry. The additional debt marginally shifts the risk-reward by lowering bankruptcy probability, but the equity still offers asymmetric downside if FDA issues persist or commercial execution falters.